AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,750.00GBp
17 Apr 2015
Change (% chg)

-78.50p (-1.63%)
Prev Close
4,828.50p
Open
4,811.00p
Day's High
4,885.00p
Day's Low
4,744.00p
Volume
3,358,199
Avg. Vol
2,623,693
52-wk High
4,946.41p
52-wk Low
3,757.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC is the United Kingdom-based global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes... (more)

Overall

Beta: 0.37
Market Cap(Mil.): £60,016.33
Shares Outstanding(Mil.): 1,263.50
Dividend: 125.00
Yield (%): 3.75

Financials

  AZN.L Industry Sector
P/E (TTM): 72.70 40.59 41.17
EPS (TTM): 0.65 -- --
ROI: 3.05 16.74 16.08
ROE: 5.75 17.27 16.92
Search Stocks

BRIEF-AstraZeneca lung cancer drug delays disease by more than a year

* Astrazeneca announces updated progression free survival data for investigational non-small cell lung cancer medicine AZD9291

17 Apr 2015

AstraZeneca lung cancer drug delays disease by more than a year

LONDON - An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at a medical meeting on Friday.

17 Apr 2015

AstraZeneca lung cancer drug delays disease by more than a year

LONDON, April 17 - An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at a medical meeting on Friday.

17 Apr 2015

BRIEF-Astrazeneca gets orphan drug status for uveal melanoma treatment

* U.S. FDA has granted orphan drug designation for mek inhibitor selumetinib, for treatment of uveal melanoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

17 Apr 2015

BRIEF-Astrazeneca, Immunocore tie-up to conduct immuno-oncology trials

* Medimmune unit entered into collaboration to conduct clinical trials in immuno-oncology with privately-held immunocore limited

16 Apr 2015

Approved Pfizer breast cancer drug impresses in latest study

- Pfizer Inc said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance, was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients.

15 Apr 2015

Approved Pfizer breast cancer drug impresses in latest study

April 15 - Pfizer Inc said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance, was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients.

15 Apr 2015

AstraZeneca science is on the move, one year on from Pfizer bid

LONDON - Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move -- quite literally.

15 Apr 2015

AstraZeneca science is on the move, one year on from Pfizer bid

* New drugs make progress, high hopes in lung cancer treatment

15 Apr 2015

Britain's FTSE sets fresh record high; Dixons, Next rally

* AstraZeneca boosted as medicine gains orphan status in U.S.

15 Apr 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks